Medicare to cover CAR-T therapy for leukemia, lymphoma

Medicare to cover CAR-T therapy for leukemia, lymphoma

A breakthrough gene therapy will be covered for certain types of lymphoma and leukemia, Medicare says.

Chimeric antigen receptor T-cell (CAR-T) boosts a patient's own immune cells to fight cancer and can cost hundreds of thousands of dollars, the Associated Press reported.

Studies have shown that CAR-T is effective against certain types of cancers, but can cause severe side effects. The use of the gene therapy to treat certain types of and lymphoma is approved by the U.S. Food and Drug Administration.

Medicare considered the matter for months before it announced its decision on Wednesday. The agency's policies on coverage can influence private insurance, the AP reported.

Explore further

Henry Ford Cancer Institute treats its first patient with innovative 'living drug' therapy

More information: AP News Article

Copyright © 2019 HealthDay. All rights reserved.

Citation: Medicare to cover CAR-T therapy for leukemia, lymphoma (2019, August 9) retrieved 19 September 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more